News Summaries

China’s Breakthrough Drugs Are Finally Getting the Market’s Attention

After two days of record‑high gains, China’s innovative‑drug sector is finally catching investors’ eyes. On June 23 and 24 several biotech stocks hit their daily limits, ending a six‑month stretch where the market seemed to ignore the industry’s progress. The reality is that Chinese companies are delivering world‑class results. At the recent ASCO meeting, 94 Chinese studies were presented, including 13 late‑breaking abstracts from 12 firms – a historic high. Akeso’s bispecific antibody ivonescumab cut the death risk for advanced squamous non‑small‑cell lung cancer by 34% and pushed median overall survival to 27.9 months, far outpacing the global benchmark set by Keytruda. Beyond the data, Chinese firms are reshaping how they go global. New co‑development and co‑commercialisation agreements with giants such as Pfizer and BMS give Chinese partners profit‑sharing rights and a seat at the table, moving from “technology export” to “capability export.” At the same time, AI is slashing discovery timelines and costs – CSPC’s AI platform cuts early‑stage research time by more than 30% and halves R&D expenses, while Crystal Pharmatech secured a $400 million AI‑driven partnership. Analysts say the market simply hasn’t re‑priced this rapid transformation yet. With strong pipelines, lucrative overseas deals, and AI‑driven efficiency, the industry is poised for an inflection point that could lift valuations dramatically for investors who can spot the shift.

China’s Breakthrough: New Drug Target Turns ‘Cold’ Tumors Hot and Beats Cancer Resistance

A research team led by Academician Yu Jinming has just reported two major discoveries that could change the way doctors treat cancer. In a paper published in Cancer Research, the scientists showed that blocking an enzyme called DGAT1 forces tumor cells to die by a process known as ferroptosis – a kind of iron‑driven cell death. DGAT1 normally helps cells store fat; when it is inhibited, fat droplets disappear, fatty acids become vulnerable to oxidation, and the resulting oxidative stress destroys the cancer cell’s protective machinery. In mouse models of melanoma, colon and breast cancer, either deleting the DGAT1 gene or giving the drug pradigastat (originally developed for other diseases) dramatically boosted the effect of anti‑PD‑1 immunotherapy, shrinking tumors that previously ignored such treatment. Single‑cell analysis revealed that DGAT1 loss attracted more CD4⁺ and CD8⁺ T cells, natural killer cells, and switched macrophages to a tumor‑fighting mode, while also increasing the visibility of cancer cells to the immune system. The team’s earlier work, published in PNAS, tackled a different problem – drug resistance – by targeting the PKC‑XIAP signaling pathway. Together, these studies offer a two‑pronged Chinese strategy: reverse resistance and turn “cold” tumors into “hot” ones, paving the way for faster clinical trials using existing DGAT1 inhibitors combined with checkpoint blockers.

What Makes a Clinical Trial Worthwhile? Five Key Pillars Redefine Global Research Standards

Too many clinical trials fall short – they ask the wrong questions, use shaky designs, or skip proper reporting, wasting money and eroding public trust. To tackle this, researchers published a new study in JAMA Network Open that asked 55 trial professionals from 16 countries what actually makes a study valuable. The participants – a mix of academic researchers, funders, ethicists, regulators, pharma staff and contract‑research groups – shared their real‑world experiences through semi‑structured interviews. Analyzing the conversations, the team identified five core dimensions that together determine a trial’s worth: **Importance** (does the question matter to patients and clinicians?), **Design** (is the methodology robust and unbiased?), **Feasibility** (can the study be carried out realistically?), **Completeness** (are all relevant outcomes captured and analyzed?), and **Reporting** (is the data shared transparently and promptly?). These pillars provide a practical checklist for anyone planning or overseeing a trial, helping to focus resources on studies that truly advance health care. By aligning industry, academia, and low‑ and middle‑income regions around these standards, the research aims to boost the credibility of medical evidence, protect participants, and speed the delivery of effective new therapies.